|
|
therapies to heal diseased and injured tissues
|
|
|
|
|
|
|
|
|
|
Research
Our Drug Development Program:
NeoCytex is developing novel regenerative therapeutics that accelerate the healing and repair of diseased tissues. Our compounds stimulate the production of healthy new cells from adult stem cells, enhancing the body’s natural ability to heal itself. The first drug candidate (NBI-18, a small molecule) is being developed as a treatment for degenerative diseases of the central nervous system. Data from animal experiments indicate that NBI-18 can speed up the production of functional new neurons from endogenous 'adult' neural stem cells.
Treatment for Neurodegenerative Diseases and Stroke:
Over 6 million Americans suffer from Parkinson's, Alzheimer’s and other neurodegenerative diseases. An additional 5.4 million patients live with the debilitating effects of stroke. There are no cures. The cost of caring for these patients will exceed $200 billion this year. Because of the complexity of the diseases and lack of well-characterized drug targets, few new candidate drugs are entering clinical trials. Use of cell transplantation therapy to repopulate the brain with healthy cells has encountered significant technical and regulatory hurdles. Our drug candidate bypasses these hurdles by directly coaxing the production of functional new neurons from preexisting neural stem cells in the brain. A safe new drug to improve neural function would be an important advance in the treatment of chronic CNS diseases.
Developmental Stage:
NBI-18 is at the preclinical testing stage. It is stable, orally bioavailable, and able to cross the blood brain barrier. In controlled assays, NBI-18 induced neurogenesis (formation of new brain cells) from precursor stem cells by up to seven-fold in aging rodents. Moreover, after four weeks, the drug-treated animals exited a maze significantly faster than the untreated group, suggesting functional recovery.
In addition to NBI-18, our research pipeline includes regenerative drug candidates that accelerate healing from wounds, fractures, and muscle injuries.
|
|
|
|
|
|
|
©2007-2008 neocytex biopharma, inc.
|
|